Pi-Medical Ltd acquired ISO 13485:2012 certification by TuV Austria Hellas

Pi-Medical Ltd welcomes you to the first newsletter for 2012 and wishes everyone a creative year. Our company, within the framework of the global economic and developmental crisis, continues to develop its products in the field of oncology with constancy and responsibility.

Full text click here

PI-Medical Ltd received a EUROSTARS grant. The project started in November 2011 and will run for 2 years.

PI-Medical has an immediate opening for a Software Developer/Engineer.

In the recent years, prostate cancer was the most commonly diagnosed cancer in men. Currently secure diagnosis

Innovative optimization technology developed by Pi-Medical used for noise barriers design.

A study on the dosimetric comparison between manual and inverse plans in HDR intracavitary/interstitial cervical cancer brachytherapy was published in the last issue of the J.

A study on the effect of dwell time restiction on the optimized prostate brachytherapy implants was published in the last issue of the J. of Contemporary Brachytherapy.

(Veenendaal, 28 September 2010) Nucletron and MedCom GmbH & Pi-Medical Ltd, today signed a license agreement for the next generation seeds treatment planning module of Oncentra Prostate.
 

DGU 2010 - Düsseldorf, Germany 22. - 25. September 2010. 62.

BiopSee® is going to be presented during the Industrial Exhibition at ESTRO Annual Congress: ESTRO 29  - 12th to 16th September 2010 Barcelona, Spain.

Pi Medical's Quality Management system, is now certified to the new ISO 9001:2008 standard by TUV Austria Hellas.

The result of cooperation between Pi Medical and University of Texas Health Science Center on biologically-based optimization, has been accepted for presentation as an oral communication in ESTRO 29, to be held in Barcelona, Spain from 12-16 September 2010.

Nucletron launched a new informational web site for patients and healthcare practitioners, www.aboutbrachytherapy.com .

The results of a study on the application of inverse planning technology for cervical cancer brachytherapy were publlished in Radiotherapy and Oncology entitled: " New inverse planning technology for image-guided cervical cancer brachytherapy: Description and evaluation within a clinical frame ".

In September 2009, the Docrates Clinic in Helsinki treated its first prostate cancer patient with HDR brachytherapy. The entire process was planned, monitored and modulated using Oncentra Prostate treatment planning software.

Two oral presentations, summarizing findings related to Pi Medical's inverse planning algorithms will be delivered at the World Congress of Medical Physics and Biomedical Engineering  2009 being held Sept. 7 -12 in Munich, Germany.

Results of HIPO evaluation were presented by two independent institutions at GEC/ESTRO/ISORT Europe Conference, held at Porto, Portugal, May 13-16, 2009. The abstracts are published in Radiotherapy & Oncology vol. 91 (1), 2009. Another study was presented in ABS Annual Meeting, held at Toronto, Ont., Canada May 31 - June 2, 2009.

Pi Medical and Medcom registered the trademark BiopSee ® in the U.S. Patent and Trademark Office.This trademark will be used for a new, advanced technology system for prostate cancer diagnosis.

The Addenbrooke's Charitable Trust (ACT) announced that Addenbrooke's Hospital was the first hospital to purchase and use Oncentra GYN. The first patient was treated last week.

A new version of HIPO, able to handle constraints related to the quality of the plan (e.g. COIN index), was presented at IMA Hot Topics Workshop “Mixed-Integer Nonlinear Optimization: Algorithmic Advances and Applications”, Nov. 17-21, 2008, Institute for Mathematics and its Applications, Minneapolis, MN, USA.

Nucletron launched Oncentra GYN , a product developed by Pi Medical and MedCom, in a special event during the World Congress of Brachytherapy.

After the positive responce of the FDA and the corresponding 510(k) clearence, Oncentra GYN can be legally marketed in the USA. 

The 1st International Real-Time HDR prostate (Oncentra Prostate) User Meeting, organized by Nucletron, was succesfully held at Athens, 24-26/1/2008. 

A set of tools for dose optimization (DVH optimization & DVH Shaper) and inverse planning (HIPO), were released with the SWIFT v.3.0 (Oncentra Prostate) by Pi-Medical.

A new algorithm for inverse treatment planning optimization, called HIPO was developed by Pi-Medical and will be presented at the 8th Biennal ESTRO Meeting (Lisboa,24-29 Sept.2005).

PROSOMA, a new 3D virtual simulation for external beam radiation therapy is now available by Pi-Medical.

Pi-Medical, after a successful audit by TUV Austria Hellas, receives EN ISO 9001:2000 certification.

SWIFT, a new system for HDR prostate treatment, developed by Pi-Medical and MedCom, is now available by Nucletron.